WEBCAST
PRESENTATIONCrinetics will host an investor conference call on June 3, 2024, at 4:30 pm Eastern Time to discuss the initial findings for atumelnant in two ongoing, open-label studies.
EVENT
Crinetics Pharmaceuticals Announces Positive Initial Findings for Atumelnant in Congenital Adrenal Hyperplasia and ACTH-Dependent Cushing’s Syndrome
Transforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
